Clinicians' Views of Patient-initiated Follow-up in Head and Neck Cancer: a Qualitative Study to Inform the PETNECK2 Trial

Autor: A. Lorenc, M. Wells, T. Fulton-Lieuw, P. Nankivell, H. Mehanna, M. Jepson, A. Karwath, B. Main, C. Firth, C. Gaunt, C. Greaves, D. Moore, E. Watson, G. Gkoutos, G. Ozakinci, J. Wolstenholme, J. Dretzke, J. Brett, J. Duda, L. Matheson, L.-R. Cherrill, M. Calvert, P. Kiely, P. Gaunt, S. Chernbumroong, S. Mittal, S. Thomas, S. Winter, W. Wong

Publikováno v: Lorenc, A, Wells, M, Fulton-Lieuw, T, Nankivell, P, Mehanna, H & Jepson, M J 2022, ' Clinicians’ views of patient-initiated follow-up in head and neck cancer : A qualitative study to inform the PETNECK2 trial ', Clinical Oncology, vol. 34, no. 4, pp. 230-240 . https://doi.org/10.1016/j.clon.2021.11.010

Aims: Current follow-up for head and neck cancer (HNC) is ineffective, expensive and fails to address patients' needs. The PETNECK2 trial will compare a new model of patient-initiated follow-up (PIFU) with routine scheduled follow-up. This article re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d6834e201611fa44bf7af50578b1b00e
https://doi.org/10.1016/j.clon.2021.11.010

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Improvement in Dysphagia Outcomes Following Clinical Target Volume Reduction in the De-ESCALaTE Study

Autor: T. Roques, T. Fulton-Lieuw, M. Vreugdenhil, Paul Sanghera, Bernadette Foran, Mehmet Sen, Hisham Mehanna, M. Evans, Charles Fong, Christopher M. Nutting, M. Dalby, Gulnaz Iqbal, Andrew Hartley, H. Yang, H. Al Booz, L. O'Toole, N. Palaniappan, Janet A. Dunn

Publikováno v: Clinical oncology (Royal College of Radiologists (Great Britain)). 33(12)

AIMS The De-ESCALaTE study showed an overall survival advantage for the administration of synchronous cisplatin chemotherapy with radiotherapy in low-risk oropharyngeal cancer when compared with synchronous cetuximab. During the trial, a radiotherapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e595865dce0d9a9f9a73dd76152b3fa
https://pubmed.ncbi.nlm.nih.gov/34340917

Cisplatin reduces costs and provides more quality adjusted life years (QALYs) than cetuximab in chemoradiotherapy for patients with HPV-positive oropharyngeal cancer (HPV+OPC)

Autor: T. Fulton-Lieuw, Alastair Gray, Hisham Mehanna, Pankaj Mistry, David A. Jones, M. Dalby, Janet A. Dunn, A. Kong

Background Results from De-ESCALaTE HPV confirmed the dominance of cisplatin over cetuximab chemoradiotherapy for tumour control in patients with HPV+OPC. We report a comparison of QoL, resource use and healthcare costs in both arms, as well as updat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f8b3babfc4fa0804baf3b1444785e41
https://ora.ox.ac.uk/objects/uuid:a6201dfd-cf4e-41a7-84bf-c62638e68343

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.